An interventional study of Cannulation with AccuVein AV400 in Liver Cirrhosis, sponsored by University Hospital, Caen. Terminated at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by University Hospital, Caen · Not applicable, Interventional, and Supportive care
availability of the principal investigator
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies in Liver Cirrhosis with a site in France — 22 open to participants now, 25 under way, 2 of them phase 3. Liver Cirrhosis · France.
Among the 95 studies in Liver Cirrhosis with a site in France, this one is the 43rd largest by enrollment of the 53 interventional ones that give a count, is one of 4 that started in 2020, is one of 29 with no phase, and was the 48th registered.
1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.
Browse Liver Cirrhosis studies →22 of the 95 studies in Liver Cirrhosis with a site in France are open now. Recruiting first, the newest first:
University Medical Center Groningen · Sites in France, Austria, Belgium and 9 more countries
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University Hospital, Grenoble · Sites in France
Ages 18+
University Hospital, Angers · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 16 · Phase 3 10
First in 2002; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 85 is close to the median of 78 across 742 interventional studies indexed under Liver Cirrhosis.
Median enrollment 205 across the 53 interventional studies, 227 across the 41 observational. Of the 63 that completed or were terminated, 11 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 95 have an industry lead sponsor. The 10 most frequent:
University Hospital, Caen is the lead sponsor of 515 studies on the registry; 84 are open to participants now.
University Hospital, Caen has 1 study filed under Liver Cirrhosis — fewer than ten, so there is no comparison to draw.
8 of the studies in Liver Cirrhosis with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05500222Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) | 2026-12 |
| NCT04530760University Hospital, LilleIntraabdominal Hypertension and Occurrence of Microaspiration in Cirrhotics Under Mechanical Ventilation | 2026-12 |
| NCT07585890University Medical Center GroningenEstablishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe | 2026-12-31 |
| NCT04613921European Foundation for Study of Chronic Liver FailureLiver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs | 2026-12-31 |
| NCT07439939Assistance Publique - Hôpitaux de ParisExploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Placement | 2027-06-09 |
Add all 8 to your calendar (.ics) → With an account.
Among the 95 studies in Liver Cirrhosis with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the effectiveness of AccuVein AV400 to facilitate placement of peripheral intravenous catheters in cirrhotic adults by comparing the success rate of the first attempt to install a peripheral venous catheter with or without AccuVein AV400®.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cirrhotic patients benefit from the support of a venous illumination device for each peripheral venous cannulation
Device: Cannulation with AccuVein AV400
Cirrhotic patients benefit from the standard technique of peripheral veinous catheter placement.
Cannulation using AccuVein AV400 device
Also known as: AccuVein AV400
First Attempt Success Rate of Cannulation
Firt attempt success of positional for each peripheral venous catheter and expressed as a percentage in cirrhotic patients during hospitalization.
Time frame: baseline
change of the score A-DIVA
Scores A-DIVA between beginning and end of hospitalization between the two groups
Time frame: baseline and end of hospitalization (up to a month)
Cost
Cost of consumables used in euro between the two groups
Time frame: baseline
Life expectancy of the catheter
Life expectancy of the catheter between the two groups
Time frame: baseline
Utilisation of a central venous catheter
Use of a central venous catheter (y/n)
Time frame: baseline
Pain's score
visual analogic scale
Time frame: baseline
Numbers of attempts
Number of attempts between two groups
Time frame: baseline
Ran from Jun 2020 to primary completion in Feb 2025, 55 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Jun 2023 → Feb 2025 and completion Jun 2023 → Dec 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
availability of the principal investigator
availability of the principal investigator
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.